Skip to content

A scoping review of assessment tools and cognitive domains for chemo brain in cancer survivors

A scoping review of assessment tools and cognitive domains for chemotherapy-induced cognitive impairments in cancer survivors - A scoping review of assessments for chemotherapy-induced cognitive impairments

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000047104
Enrollment
Unknown
Registered
2022-03-08
Start date
2021-12-17
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cancer

Interventions

None listed

Sponsors

Kitasato University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: We searched three online databases: PubMed, CINAHL, and Web of Science. Search limits included peer-reviewed studies, published in English, by October 1st, 2021. The commencing year limit was not set, and all research articles were traced back. The inclusion criterion for the present review was the prospective study principally investigated the effects of chemotherapy on cognition for adults with cancer. However, studies that investigated other cancer treatments separately from chemotherapy were included if they had a chemotherapy treatment group alone.

Exclusion criteria

Exclusion criteria: The exclusion criteria for our study are as follows: (1) no abstract (2) languages other than English (3) review article, interventional trial, and case study (4) experiments with animals (5) primary brain tumor or brain metastasis (6) unclear distinction between hormone therapy and radiation therapy (7) having any other reason that the reviewer finds to be an obvious content discrepancy. As an example of this content inconsistency, in order to examine the effect of chemotherapy treatment on cognitive impairment more purely, we excluded cases in which the main topic of the previous study was considered by the reviewers to be strongly influenced by depression, anxiety, fatigue, or anemia.

Design outcomes

Primary

MeasureTime frame
Neuropsychological assessment tool

Secondary

MeasureTime frame
Patient reported outcome Neuroimaging assessment tool

Countries

Japan

Contacts

Public ContactKazuya Saita

Hiroshima University Graduate school of Biomedical and Health Sciences

saita@hiroshima-u.ac.jp082-257-5452

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026